Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Genitourinary tumours, prostate

3826 - Prospective comprehensive genomic profiling (CGP) of 3,343 primary and metastatic site prostate tumors


21 Oct 2018


Poster Discussion session - Genitourinary tumours, prostate


Translational Research

Tumour Site

Prostate Cancer


Siraj Ali


Annals of Oncology (2018) 29 (suppl_8): viii271-viii302. 10.1093/annonc/mdy284


S.M. Ali1, J. Chung2, N. Dewal3, L.M. Gay4, Y. He3, E.S. Sokol3, S.Z. Millis3, J.K. Killian3, A.B. Schrock5, S.K. Pal6, V.A. Miller3, J.S. Ross3, N. Agarwal7

Author affiliations

  • 1 Clinical Development, Foundation Medicine, Inc., 02141 - Cambridge/US
  • 2 Clinical Development, Foundation Medicine, 02141 - Cambridge/US
  • 3 Genetics, Foundation Medicine, Inc., Cambridge/US
  • 4 Pathology, Foundation Medicine, 02141 - Cambridge/US
  • 5 Clinical Development, Foundation Medicine, Inc., MA 02141 - Cambridge/US
  • 6 Medical Oncology, City of Hope, 91010 - Duarte/US
  • 7 Oncology/ Internal Medicine, Huntsman Cancer Institute, 84112 - Salt Lake City/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3826


Sequencing of prostate cancer has identified genomic alterations (GAs) with therapeutic implications (PMID: 29694820). To more fully inform targeted treatment strategies, we performed prospective CGP on 3,343 prostate tumors to better define the spectrum of GAs and assess signatures of genomic instability in primary and metastatic site tumors.


Prostate cancer samples (1,525 primary site, 1,818 metastatic site) were assessed by hybrid capture-based CGP for all exons of 395 genes and select introns for 31 genes. Results were analyzed for base substitutions, short insertions/deletions (indels), rearrangements, and copy number alterations, as well as genomic signatures including genome-wide loss of heterozygosity (LOH), microsatellite instability (MSI) status and tumor mutational burden (TMB).


There was an average of 4.6 GAs per tumor. Frequently altered genes were TP53 (45%), PTEN (33%), TMPRSS2-ERG (31%) and AR (23%). Targetable BRAF/RAF1 fusions were mutually exclusive with ETS fusions. The PI3K (41%), G1/S cell cycle (24%) and WNT (16%) pathways were frequently altered. DNA repair GAs were frequent and included homologous recombination repair (HRR) (22%), Fanconi Anemia (4%), and mismatch repair (MMR) (4%) pathway GAs; 39% of DNA repair mutations were predicted to be germline. BRCA1/2, ATR and FANCA GAs were associated with high genome-wide LOH. Overall median TMB was low (2.6 mutations/Mb), although a subset (3%) were TMB-High; 71% of TMB-High cases were MSI-High. Metastatic tumors were enriched in AR, LYN, 11q13 amplicon (CCND1/FGF19/FGF4/FGF3), MYC, NCOR1, CDKN2A, RB1, and CTNNB1 GAs. AR GAs associated with anti-androgen resistance were frequent in metastatic site samples including amplification (28%), mutations (12%), and rearrangements (2%).


Routine CGP frequently identified GAs that may inform targeted therapy or trial selection for metastatic prostate cancer: PI3K pathway GAs, HRR pathway GAs, and MSI-High/TMB-High genomic signatures may inform PI3K/AKT inhibitor targeted therapy, PARP inhibitors, and immunotherapy, respectively. DNA repair mutations were frequently germline, and patients with such mutations may require further testing and genetic counselling.

Clinical trial identification

Legal entity responsible for the study

Foundation Medicine.


Has not received any funding.

Editorial Acknowledgement


S.M. Ali, J. Chung, N. Dewal, L.M. Gay, Y. He, E.S. Sokol, S.Z. Millis, J.K. Killian, A.B. Schrock, V.A. Miller, J.S. Ross: Employee: Foundation Medicine. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.